Welcome to our dedicated page for Telo Genomics news (Ticker: TDSGF), a resource for investors and traders seeking the latest updates and insights on Telo Genomics stock.
Telo Genomics Corp. (TDSGF) delivers cutting-edge telomere analysis solutions for precision oncology diagnostics through its AI-powered TeloView platform. This news hub provides investors and healthcare professionals with essential updates on clinical validations, regulatory progress, and strategic partnerships.
Access timely reports on multiple myeloma diagnostic advancements, liquid biopsy innovations, and intellectual property developments. Our curated collection includes earnings announcements, research collaborations with leading institutions, and technology licensing updates that demonstrate the company's market leadership.
Bookmark this page for consolidated access to verified updates about TDSGF's 3D telomere profiling breakthroughs and CLIA-certified testing solutions. Stay informed about developments in genomic instability assessment and AI-driven prognostic tools that are reshaping cancer care standards.
Telo Genomics announced the publication of results from its smoldering multiple myeloma (SMM) study in the American Journal of Hematology. The study, involving 168 patients, demonstrated superior performance of the TeloViewSMM test with an 85% positive predictive value and a 73% negative predictive value. The test, developed in collaboration with Mayo Clinic, distinguishes high-risk SMM patients from stable ones, aiding in treatment decisions. This non-invasive test addresses a critical need in SMM management and has potential applications in other cancers.
Telo Genomics (TSXV: TELO, OTCQB: TDSGF), a biotech firm specializing in telomere technology for oncology diagnostics, has entered into a collaboration with Emery Pharma, a CRO specializing in biologic drug development.
This partnership aims to merge their innovative technologies to provide enhanced bioanalytical solutions for clinical research. The TeloView platform from Telo offers high-sensitivity genomic instability insights, while Emery Pharma delivers comprehensive biologic characterization services.
The Memorandum of Understanding (MOU) sets the stage for collaborative efforts to address unmet needs in pharma and diagnostics. Executives from both companies expressed optimism about the potential synergies and future developments.
FAQ
What is the current stock price of Telo Genomics (TDSGF)?
What is the market cap of Telo Genomics (TDSGF)?
